These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11371940)

  • 21. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer.
    Phan TP; Syed AM; Puthawala A; Sharma A; Khan F
    J Urol; 2007 Jan; 177(1):123-7; discussion 127. PubMed ID: 17162020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High dose rate and external beam radiotherapy in locally advanced prostate cancer.
    Viani GA; Pellizzon AC; Guimarães FS; Jacinto AA; dos Santos Novaes PE; Salvajoli JV
    Am J Clin Oncol; 2009 Apr; 32(2):187-90. PubMed ID: 19307949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy.
    Colecchia M; Frigo B; Del Boca C; Guardamagna A; Zucchi A; Colloi D; Leopardi O
    J Clin Pathol; 1997 May; 50(5):384-8. PubMed ID: 9215120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
    Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
    J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer.
    D'Alimonte L; Helou J; Sherman C; Loblaw A; Chung HT; Ravi A; Deabreu A; Zhang L; Morton G
    Brachytherapy; 2015; 14(3):309-14. PubMed ID: 25466361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT.
    Pe ML; Trabulsi EJ; Kedika R; Pequignot E; Dicker AP; Gomella LG; Valicenti RK
    Urology; 2009 Jun; 73(6):1328-34. PubMed ID: 19376564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue.
    Xie X; Clausen OP; De Angelis P; Boysen M
    Cancer; 1999 Sep; 86(6):913-20. PubMed ID: 10491515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
    Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
    Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High dose combination radiotherapy for the treatment of localized prostate cancer.
    Zeitlin SI; Sherman J; Raboy A; Lederman G; Albert P
    J Urol; 1998 Jul; 160(1):91-5; discussion 95-6. PubMed ID: 9628612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
    Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
    Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.
    Santini D; Tonini G; Vecchio FM; Borzomati D; Vincenzi B; Valeri S; Antinori A; Castri F; Coppola R; Magistrelli P; Nuzzo G; Picciocchi A
    J Clin Pathol; 2005 Feb; 58(2):159-65. PubMed ID: 15677536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.
    Ragde H; Korb LJ; Elgamal AA; Grado GL; Nadir BS
    Cancer; 2000 Jul; 89(1):135-41. PubMed ID: 10897010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review).
    Szostak MJ; Kyprianou N
    Oncol Rep; 2000; 7(4):699-706. PubMed ID: 10854529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma.
    Yamoah K; Eldredge-Hindy HB; Zaorsky NG; Palmer JD; Doyle LA; Sendecki JA; Hesney AA; Harper L; Repka M; Showalter TN; Hurwitz MD; Dicker AP; Den RB
    Brachytherapy; 2014; 13(5):456-64. PubMed ID: 24953945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer.
    Zelefsky MJ; Whitmore WF
    J Urol; 1997 Jul; 158(1):23-9; discussion 29-30. PubMed ID: 9186315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy.
    Potters L; Torre T; Ashley R; Leibel S
    J Clin Oncol; 2000 Mar; 18(6):1187-92. PubMed ID: 10715287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA ploidy measured on archived pretreatment biopsy material may correlate with prostate-specific antigen recurrence after prostate brachytherapy.
    Keyes M; Macaulay C; Hayes M; Korbelik J; Morris WJ; Palcic B
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):829-34. PubMed ID: 23688814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.